Dr. Kenneth Kalunian discusses the Lupus Foundation of America Collective Data Analysis Initiative (LFA CDAI) which is providing insight into the impact various background medications may have on lupus clinical trial outcomes.
Dr. Murray Urowitz discusses current and potential new therapies for managing lupus.
Dr. Richard Furie of the North Shore-Long Island Jewish Health System provides an overview of how lupus is treated.
Dr. Emily von Scheven of the University of California at San Francisco discusses the development of consensus treatment plans for proliferative nephritis in juvenile systemic lupus.
Dr. Michelle Petri of the Johns Hopkins University Medical Center discussed the results of a study of vitamin D supplementation in people with lupus.
Dr. Eyal Muscal of the Baylor School of Medicine reports on the results of a study that used advanced brain imaging to evaluate changes in the brains of adolescents with lupus.
Dr. Anne Stevens of the University of Washington, Seattle Children’s Hospital discusses her study to evaluate the role of the protein PD-L1 to help doctors determine whether an illness is lupus-related or the result of an infection.
Dr. Kenneth Kalunian discusses the results of a study to examine the effect of background medications taken by individuals enrolled in lupus clinical trials.